Breakthrough Discovery of Two New Subtypes of Multiple Sclerosis

Recent research has identified two new biological subtypes of multiple sclerosis (MS) using artificial intelligence, which could significantly enhance treatment personalization and patient outcomes. Conducted by University College London (UCL) and Queen Square Analytics, the study involved 600 patients and utilized a machine learning model named SuStaIn to analyze blood levels of serum neurofilament light chain (sNfL) alongside MRI scans. The findings, published in the medical journal *Brain*, categorize MS into early sNfL and late sNfL subtypes.

The Guardian

The early sNfL subtype is characterized by high sNfL levels and rapid development of brain lesions, indicating a more aggressive form of the disease. Conversely, the late sNfL subtype shows brain shrinkage in specific areas before sNfL levels increase, suggesting a slower progression of damage. This differentiation allows for a more nuanced understanding of MS, which has traditionally been classified based on clinical symptoms rather than underlying biological processes.

The Guardian

The identification of these subtypes is expected to transform how MS is treated. Dr. Arman Eshaghi, the lead author of the study, emphasized that the current classification systems do not adequately reflect the complexities of the disease. He noted that the new AI-driven approach could enable healthcare providers to tailor treatments based on the specific subtype a patient has, potentially leading to better management of the disease. For instance, patients identified with early sNfL MS may qualify for more aggressive therapies, while those with late sNfL could receive treatments aimed at protecting brain cells.

The Guardian

Caitlin Astbury, senior research communications manager at the MS Society, highlighted the importance of this development in understanding MS. She pointed out that existing treatment options are often limited and that a deeper biological understanding could lead to more effective therapies that halt disease progression.

The Guardian

Despite the promising findings, some experts caution that the transition from symptom-based classifications to biologically informed ones may face challenges. The complexity of MS and the variability in patient responses to treatment necessitate careful consideration of how these new subtypes will be integrated into clinical practice. Astbury noted that while there are approximately 20 treatment options for relapsing MS, many patients still lack effective therapies, underscoring the need for ongoing research.

The Guardian

• “The lead author of the study, UCL’s Dr Arman Eshaghi, said: “MS is not one disease and current subtypes fail to describe the underlying tissue changes, which we need to know to treat it.” — Dr. Arman Eshaghi, UCL

The Guardian

• “ Caitlin Astbury, senior research communications manager at the MS Society, a charity, said: “This is an exciting development in our understanding of MS.” — Caitlin Astbury, MS Society

The Guardian

The research represents a significant step forward in the quest for personalized medicine in MS, with the potential to improve the quality of life for millions affected by the disease.

The Guardian